Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 4 THRIVE Data Highlights Eptinezumab’s Impact on Migraine After Prior CGRP Failure
2
7 Cerebral Palsy Agents to Watch, Gluten-Free Diet Improves Cognition and Quality of Life in PD, Real-World Data on Treatment Transitions to Nipocalimab in gMG
3
Defining Precision Medicine in Multiple Sclerosis
4
NeurologyLive® Brain Games: October 11, 2026
5